comparemela.com

Latest Breaking News On - Product candidate - Page 6 : comparemela.com

IMV Inc. Announces First Quarter 2022 Financial and Operational Results

Press release content from Business Wire. The AP news staff was not involved in its creation.

Australia
United-states
New-zealand
Canada
Massachusetts
America
Canadian
American
Andrew-hall
Michaelp-bailey
Relationsjoy-bessenger
Linkedin

Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza® (evinacumab) Outside the United States

/PRNewswire/ Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Ultragenyx Pharmaceutical Inc. today announced a license and collaboration agreement for.

United-states
Georged-yancopoulos
Regeneron-velocimmune
Emild-kakkis
Regeneron-pharmaceuticals-inc
Exchange-commission-on
Ultragenyx-pharmaceutical-inc
Twitter
Regeneron-genetics-center
European-commission
Nasdaq
Teva-pharmaceutical-industries-ltd

Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza® (evinacumab) Outside the United States

/PRNewswire/ Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Ultragenyx Pharmaceutical Inc. today announced a license and collaboration agreement for.

United-states
Georged-yancopoulos
Regeneron-velocimmune
Emild-kakkis
Regeneron-pharmaceuticals-inc
Exchange-commission-on
Ultragenyx-pharmaceutical-inc
Twitter
Regeneron-genetics-center
European-commission
Nasdaq
Teva-pharmaceutical-industries-ltd

Basilea Pharmaceutica AG: Basileas Partner Asahi Kasei Pharma reicht Antrag auf Marktzulassung (NDA) von Isavuconazol in Japan ein

Ad hoc-Mitteilung gemäss Art. 53 KR Basel, 30. September 2021 Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass ihr Partner Asahi Kasei Pharma Corporation (Asahi Kasei Pharma) in Japan

Germany
Norway
Australia
Iceland
United-states
Liechtenstein
Canada
Russia
Switzerland
Turkey
America
German

Adagio Therapeutics, Inc.: Adagio Therapeutics kündigt neue Daten über Potenzial von ADG20 zur Behandlung und Prävention von COVID-19 an

ADG20 ist bei gesunden Probanden weiterhin gut verträglich; im Rahmen der laufenden Phase-I-Studie wurde eine längere Halbwertszeit und eine Virenneutralisationswirkung in Serum über sechs Monate beobachtet Daten

Development-programs
Forward-propositional-this-press
Marketing-solutions-for-infectious-diseases
New-data
Iii-studies
Marketing-solutions
Infectious-diseases
Study-participants
Background-information
Anti-body
For-administration

vimarsana © 2020. All Rights Reserved.